Regenerative Ocular Immunobiologics Llc
Clinical trials sponsored by Regenerative Ocular Immunobiologics Llc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drop trial targets chronic dry eye in transplant survivors Results expected Dec 2026 (estimated)
- Can a new eye drop soothe the burning dryness of ocular GVHD? Results expected Mar 2027 (estimated)
-
Can a new eye drop soothe the burning dryness of ocular GVHD?
Disease control Recruiting nowThis Phase 3 trial tests whether an experimental eye drop called d-MAPPS can reduce eye surface damage and ease symptoms like dryness and discomfort in adults with chronic ocular graft-versus-host disease (oGVHD), a complication of stem cell transplants. Participants will use the…
Phase 3 • Sponsor: Regenerative Ocular Immunobiologics LLC • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for chronic dry eye from Graft-Versus-Host disease: expanded access to d-MAPPS eye drops
Disease control Expanded accessThis expanded access program makes an investigational eye drop called d-MAPPS available to adults with chronic ocular graft-versus-host disease (oGVHD), a painful dry eye condition that can occur after a stem cell or bone marrow transplant. The treatment is a protein-based soluti…
Sponsor: Regenerative Ocular Immunobiologics LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC